Ozempic Face: What It Is, Why It Happens, and What You Can Do
Ozempic face is a colloquial term for the sunken, aged look that can follow rapid weight loss on semaglutide. It is not a medically recognized condition and poses no serious health risk, but options like fillers, skin-tightening procedures, and surgery can address the volume loss.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Ozempic face is a slang term for the gaunt, hollowed look some people get after losing weight quickly on semaglutide (Ozempic, Wegovy) or similar GLP-1 drugs. It is not a medically recognized condition [3], and it is primarily a consequence of rapid weight loss itself rather than a direct side effect of the drug [3]. The same facial changes occur after bariatric surgery or restrictive dieting [3]. It cannot always be prevented, but slower weight loss gives the skin time to adjust [3], and both nonsurgical options like dermal fillers and surgical options like a face lift can treat the changes [1]. The skin may return toward a more natural state over time, though this depends on age, weight, and how long a person lived with obesity [3].
What is Ozempic face?
The term was first used in 2023 by the American dermatologist Dr. Paul Jarrod Frank to describe a marked reduction in facial volume and soft tissue definition after rapid semaglutide-induced weight loss [2]. It has since been applied more broadly to facial changes after any significant, rapid weight loss, whatever the cause, including dieting without medication [2].
Ozempic face is a colloquial term, not a medically recognized diagnosis [3]. It sits alongside other media coinages like “Ozempic butt” and “Ozempic body” that describe tissue volume loss during medication-assisted weight loss [1].
What does Ozempic face look like?
The most visible features are sunken cheeks and temples, with the bones of the face appearing more prominent [3]. Fat loss in the temples, cheeks, tear troughs, jawline, marionette lines, and nasolabial folds can make the face look gaunt and resemble advanced facial aging [1, 2].
Other reported changes include [1, 2]:
- Smaller lips, cheeks, and chin
- Increased skin laxity and deeper wrinkles
- A hollowed or sunken area around the eyes
- More prominent cheekbones
Rapid nutrient depletion during weight loss can also reduce fatty acids, weakening the skin barrier and causing dryness and a lack of shine [1]. One review noted that patients with significant weight loss may look up to 5 years older than peers who did not lose weight [1].
Why does the face change on GLP-1 drugs?
The weight loss caused by semaglutide is typically rapid and affects the entire body, including the face [2, 3]. The problem is one of timing: the skin’s intrinsic remodeling capacity cannot keep pace with the accelerated depletion of subcutaneous fat underneath it [2]. The result is loose skin over a thinner fat layer, which makes wrinkles and sagging more pronounced [2].
Cellular changes during this process include decreased levels of collagen and elastin [1]. A systematic review found that evidence for GLP-1 receptor agonists preferentially causing facial fat atrophy is lacking; one theory is that the drugs merely emphasize the age-related gradual decrease in elastin turnover by accentuating sagging skin [1].
Is it the drug or the weight loss?
The evidence points to the weight loss. Bariatric surgeon Dr. Andrea Bedrosian describes the facial changes as primarily a consequence of rapid weight loss itself, not a direct side effect of Ozempic, and notes that similar changes occur after bariatric surgery and restrictive diets [3]. The phenomenon is not new; it is simply more visible now because so many more people are on the medication [3]. About 13% of US adults, roughly 32 million people, have used a GLP-1 receptor agonist at some point [1].
The changes are likely common to the whole drug class rather than unique to semaglutide, including tirzepatide, sold as Mounjaro [2].
Who is more likely to notice it?
The effect is more pronounced in older people, who naturally have lower collagen levels [1]. It is also linked to losing a large amount of weight in a short period [2, 3].
For context on how much weight is involved, the STEP 1 body-composition substudy followed adults taking semaglutide 2.4 mg for 68 weeks. The results show the scale of change that medication-assisted weight loss can produce [5]:
| Measure (68 weeks) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Body weight | -15.0% | -3.6% |
| Total fat mass | -19.3% | — |
| Visceral fat mass | -27.4% | — |
| Lean body mass | -9.7% | — |
That substudy included 140 participants and also found that lean tissue made up a 3.0 percentage point larger share of total body mass by the end, since fat mass fell faster than lean body mass [5]. One review notes that moderate medication-assisted weight loss typically does not exceed about 25% of body weight [1].
What is Ozempic butt?
“Ozempic butt” is a related buzzword for sagging in the buttocks after rapid weight loss. Dr. Bedrosian says it is not a common complaint in her practice, but sagging can certainly occur after rapid weight loss, and it is most noticeable in areas with a lot of tissue and fat: the butt, belly, thighs, and face [3]. Similar changes in breast, body, and buttock shape have been reported with this class of medications [1].
Is hair loss related?
Hair loss is a separate signal, but it appears in the same context of rapid weight loss and nutritional change. In the Wegovy injection trials in adults, hair loss was reported by 3% of patients on the drug versus 1% on placebo [4].
A BMJ study published July 22, 2026, using Penn Medicine health records of adults with type 2 diabetes, found GLP-1 receptor agonist use was associated with a higher risk of alopecia than SGLT-2 inhibitors (hazard ratio 1.37) and DPP-4 inhibitors (hazard ratio 1.68) [6]. This was an observational study, so it shows an association, not cause and effect. The association was specific to non-scarring hair loss, and the absolute risk was low [6]. Weight loss and changes in nutritional status are established risk factors for telogen effluvium, a common and typically transient form of non-scarring hair loss, which offers a plausible mechanism [6].
Can Ozempic face be prevented?
There is no guaranteed way to prevent it, but a slower, more controlled weight loss allows the skin time to adjust and can minimize sagging [3]. Any dosage adjustments belong in the hands of the prescribing physician, and weight-loss goals and concerns about facial changes are worth discussing with a doctor or registered dietitian [3].
Regular exercise, a balanced diet, and proper hydration support skin health and elasticity [3]. One review also argues that patients should be counseled about the potential impact on fat distribution before these medications are prescribed, so they can weigh the pros and cons against their personal goals [1].
What nonsurgical treatments exist?
Treatment depends on the severity of the changes and patient preferences [1]. Injectable dermal fillers are one option for restoring lost facial volume. The most common fillers are made of hyaluronic acid, with other options including calcium hydroxyapatite, poly-L-lactic acid, polymethylmethacrylate, and autologous fat transfer [1]. Collagen stimulators and skin-tightening techniques such as radiofrequency microneedling and CO2 laser therapy can also restore facial balance [1].
Stopping or switching medications is another option, but it carries the risk of rebound weight gain, which may not be ideal for patients who have achieved significant weight and cardiometabolic improvements [1].
One case series from Italy reported on endotissutal bipolar radiofrequency (BodyTite) in 24 patients aged 27 to 65, with at least 12 months of follow-up. Most patients rated their satisfaction at 8 or higher on a 0-to-10 scale, and the only adverse event was transient redness in 4 patients [2]. This was a small, uncontrolled case series, so it describes one group’s experience rather than proof of effectiveness.
What surgical treatments exist?
For more extensive changes, face and neck lift surgeries address the excess skin that weight loss can leave behind. Some patients develop prominent neck bands that can be treated with platysmaplasty [1]. Facial fat grafting is often a useful complementary procedure for volume loss, and it typically requires more volume than standard facial rejuvenation [1].
Dr. Bedrosian recommends a cautious approach: address the rapid weight loss that caused the facial changes first, and anyone still considering surgery should consult a board-certified plastic surgeon experienced in facial volume loss, who can evaluate individual needs and discuss the risks and benefits [3].
Public interest tracks this demand. Google searches for “Ozempic face” have been rising since January 2023 and peaked in April 2024, and those searches were linked to rising searches for “face filler” and “plastic surgeons” [1].
Is Ozempic face permanent?
Not necessarily. After significant weight loss, the skin needs time to adjust and may return to a more natural state on its own. How much it recovers depends on factors like age, weight, and how long the person lived with obesity or overweight [3].
Two caveats temper that outlook. First, when weight is regained, fat distribution rarely returns to its pre-loss pattern, which can contribute to lasting signs of facial aging [1]. Second, in one extension trial, patients regained two-thirds of their lost weight within a year of stopping semaglutide [1].
How serious is it compared with other side effects?
Ozempic face poses no serious health risk, according to Dr. Bedrosian, though the distress it causes is valid and worth raising with a doctor [3].
The Wegovy label carries a boxed warning about the risk of thyroid C-cell tumors, based on rodent studies where the human relevance has not been determined [4]. The label’s other warnings include acute pancreatitis, gallbladder disease, acute kidney injury from volume depletion, severe gastrointestinal reactions, and pulmonary aspiration during general anesthesia or deep sedation [4].
Sources
- PubMed Central. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.
- PubMed Central. “Ozempic Face”: An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)—Our Experience.
- Northwell Health. Ozempic face: The cosmetic concerns of rapid weight loss. December 5, 2025.
- US Food and Drug Administration. WEGOVY (semaglutide) prescribing information. 2026.
- PubMed Central. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.
- The BMJ. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. July 22, 2026.
Frequently asked questions
Is Ozempic face permanent?
Not always. After significant weight loss, the skin needs time to adjust and may return to a more natural state on its own, depending on age, weight, and how long a person lived with obesity. However, fat distribution rarely returns to its pre-loss pattern if weight is regained, which can leave lasting signs of facial aging.
Does Ozempic face happen with Mounjaro or Zepbound?
The facial changes are likely common to the whole GLP-1 receptor agonist class, including tirzepatide, which is sold as Mounjaro, rather than being unique to semaglutide. The changes stem from rapid weight loss itself, which these medications all promote [2, 3].
Can Ozempic face be prevented?
There is no guaranteed prevention, but slower, more controlled weight loss gives the skin time to adjust and can minimize sagging. Regular exercise, a balanced diet, and proper hydration support skin health and elasticity. Any dosage adjustments should only be made by the prescribing physician.
Do fillers fix Ozempic face?
Injectable dermal fillers are one option for restoring lost facial volume. Hyaluronic acid fillers are the most common, with options including calcium hydroxyapatite, poly-L-lactic acid, polymethylmethacrylate, and autologous fat transfer. The choice of treatment depends on the severity of the changes and patient preferences.
What is Ozempic butt?
Ozempic butt is a media term for sagging skin in the buttocks after rapid weight loss. Bariatric surgeon Dr. Andrea Bedrosian says it is not a common complaint, but sagging can occur after rapid weight loss and is most noticeable in areas with a lot of tissue and fat, like the butt, belly, thighs, and face.
Does Ozempic face happen without medication?
Yes. The term now describes facial changes after any significant rapid weight loss, whatever the cause, including caloric restriction or lifestyle change without medical supervision. Similar changes occur after bariatric surgery and restrictive diets.
Will Ozempic face go away if I stop the drug?
The skin may return toward a more natural state over time, depending on factors like age, weight, and how long a person lived with obesity. But stopping carries a trade-off: in one extension trial, patients regained two-thirds of their lost weight within a year of stopping semaglutide, and fat distribution rarely returns to its pre-loss pattern on regain.
Is hair loss related to Ozempic face?
They are separate signals but share a context of rapid weight loss. Wegovy injection trials in adults reported hair loss in 3% of patients versus 1% on placebo. A BMJ observational study in adults with type 2 diabetes found GLP-1 receptor agonists were associated with higher alopecia risk, with a hazard ratio of 1.37 versus SGLT-2 inhibitors, though the absolute risk was low.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.